雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Somatostatin receptor imaging and nuclear medicine treatment Ryota Nakashima 1 1Department of Radiation Oncology and Image-Applied Therapy Kyoto University Hospital Keyword: ソマトスタチン受容体イメージング , PRRT , 神経内分泌腫瘍 pp.245-255
Published Date 2025/3/10
DOI https://doi.org/10.18888/rp.0000002859
  • Abstract
  • Look Inside
  • Reference

Neuroendocrine tumors(NET)often express somatostatin receptors(SSTR), and somatostatin receptor imaging(SRI), a nuclear medicine test targeting SSTRs, is used to detect and qualitatively diagnose lesions. In principle, surgical resection is the first choice for NET limited to localized regions, but for unresectable cases or cases of distant metastasis, systemic therapies such as somatostatin analogues(SSA), mTOR inhibitors, and chemotherapy are considered. In addition, 177Lu-DOTATATE, a drug in which a peptide that binds to SSTR is labeled with a beta-emitting radioisotope, has been available for use in insurance-covered medical treatment in Japan since 2021. This type of RI therapy is called peptide receptor radionuclide therapy(PRRT), and the role of SRI as a companion diagnostic for PRRT is becoming increasingly important. In this article, we will explain 177Lu-DOTATATE, one of the SRI and PRRT treatment drugs, while also discussing evidence and case studies at our hospital.


Copyright © 2025, KANEHARA SHUPPAN Co.LTD. All rights reserved.

基本情報

電子版ISSN 印刷版ISSN 0009-9252 金原出版

関連文献

もっと見る

文献を共有